Ardelyx (MEX:ARDX) Stock Based Compensation: MXN933 Mil (TTM As of Mar. 2026)


MEX:ARDX Ardelyx Inc MEX:ARDX
69 GF Score
Price MXN99.00
GF Value MXN216.64
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Stock Based Compensation?

Ardelyx MEX:ARDX 69 Stock Based Compensation is MXN933 Mil as of Mar. 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN216.64 (Possible Value Trap). The stock has 6 warning signs investors should review.

Ardelyx's Stock Based Compensation for the three months ended in Mar. 2026 was MXN255 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN933 Mil.

Ardelyx Stock Based Compensation Related Terms

Ardelyx Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Ardelyx's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Stock Based Compensation Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 246.97 209.58 229.66 779.61 881.60

Ardelyx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 247.30 220.06 233.74 224.08 255.31
MEX:ARDX
69GF Score
Ardelyx Inc MEX:ARDX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN933 Mil.

What does a Stock Based Compensation of MXN933 Mil mean?
Ardelyx (MEX:ARDX) has a Stock Based Compensation of MXN933 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ardelyx and its competitors.
Is Ardelyx's Stock Based Compensation too high?
Ardelyx's current Stock Based Compensation is MXN933 Mil. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Stock Based Compensation compare to AVLN and INBX?
Ardelyx's Stock Based Compensation of MXN933 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ardelyx and its competitors. Ardelyx's current Stock Based Compensation is MXN933 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN216.64, compared to a current price of MXN99.00 — trading 54.3% below its estimated fair value. The current Stock Based Compensation is MXN933 Mil. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Stock Based Compensation is MXN933 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (MEX:ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of MXN99.00 is trading 54.3% below its estimated GF Value™ of MXN216.64. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for MEX:ARDX:

  • Stock Based Compensation: MXN933 Mil
  • GF Value™: MXN216.64 vs. price of MXN99.00 (54.3% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:USA41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score

Get the complete analysis for MEX:ARDX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN99.00
Price
MXN216.64
GF Value